Torrent Pharmaceuticals Limited
It is ahmedabad based company Pharmaceuticals company.Torrent was renamed from 'Trinity'. iT also focused on establishing its own manufacturing facilities in the early 80s and involves in therapeutic areas including cardiovascular,central nervous system, diabetology and painmanagement segments.
The key factor for success of Torrent is that they have taken steps towards in low-cost facilities by shifting manufacturing to india ,improvement in sales productivity, and linking the product pipeline for regulated markets with Heumann.
Sound Infrastructure
During 2005-06, the company established a new manufacturing facility in Baddi (Himachal Pradesh),expanded its R&D facility at Bhat, as well asexpanded and upgraded the Active PharmaceuticalIngredient manufacturing facility at Chhatral.The company also launched 43 new products in the market as compared to 22 in the previous year
Products for the Global Generics Market
Torrent Pharmaceuticals Limited Inc., the US subsidiary of Torrent,filed four Abbreviated New Drug Applications and three Drug Master Files (DMFs) during theyear.Torrent Pharmaceuticals company expects this to help it indevelopment of DMFs for API, generic formulationsand novel dosage forms for Europe, the US andregulated markets.
Torrent R & D Centre has a team of over 560 scientists, who continue to offer dedicated services in the areas of Discovery Research, Generic Drug Development and New Drug Delivery Systems/Value added generics. Thereby transforming discoveries into the highest quality therapeutic products.
Set up at an investment of over US $ 40 million, the R&D Centre conforms to international quality standards and houses the most advanced and up to date equipments. It has one of the most advanced infrastructures for both basic and applied research.
Currently, Torrent has seven discovery projects in pipeline – 3 in Diabetes & related complications, 1 in cerebro-vascular, 2 in obesity and 1 in cardio-vascular. Torrent has filed 219 patents for NCEs in all major markets worldwide; the patent offices of USA, Japan, Europe, Czech Republic, Australia, Hong Kong, Russia and India have granted / accepted 123 patents so far.
Opportunities for undertaking contract and collaborative research are being actively pursued. There would be a distinct focus on out-licensing of its NCEs for development and global marketing.
you can go to my home page by clicking Vikram Engineer